Registry-listed formulations

azelastine hydrochloride · chembl:CHEMBL1200809

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

21 source entries across 17 studies. This list may not include all unresolved or historical entries.

  • azelastine HclRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.15% Azelastine HydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.15% azelastine hydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.1% azelastine hydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.15% azelastine hydrochloride Nasal SprayRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.15% azelastine hydrochloride 1644 mcg dailyRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.1% azelastine hydrochloride 1096 mcg dailyRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.15% azelastine hydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 0.15% azelastine hydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastine HCl Nasal Spray, 0.1%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastine HCl (Astelin) Nasal Spray, 137 mcgRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastine hydrochloride nasal spray 0.15%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastine hydrochloride nasal spray 0.10%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • azelastine hydrochloride 0.15% Nasal SprayRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 205.5 mcg of azelastine hydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 137 mcg of azelastine hydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastine HydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastine HydrochlorideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • azelastine hydrochloride 0.05%Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Azelastin COMOD 0,5 mg/ml Augentropfen, LösungRegistry product

    Molecular identity unconfirmed

    Formulation reported by source: EYE DROPS, SOLUTION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
66.7%

Based on 15 completed trials

Completion Rate
94%(15/16)
Active Trials
0(0%)
Results Posted
73%(11 trials)
Terminated
1(6%)

Phase Distribution

Phase 1
1
6%
Phase 2
1
6%
Phase 4
4
25%
Phase 3
10
63%

Phase Distribution

1

Early Stage

1

Mid Stage

14

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
1(6.3%)
Phase 3Large-scale testing
10(62.5%)
Phase 4Post-market surveillance
4(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.8%

15 of 16 finished

Non-Completion Rate

6.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(15)
Terminated(1)

Detailed Status

Completed15
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (6.3%)
Phase 21 (6.3%)
Phase 310 (62.5%)
Phase 44 (25.0%)

Trials by Status

terminated16%
completed1594%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_4

Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction

NCT06800274
terminatedphase_1

Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis

NCT05887843
completedphase_3

Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients

NCT04729517
completedphase_4

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

NCT01880840
completedphase_3

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

NCT00720382
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06800274Phase 4

Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction

Completed
NCT05887843Phase 1

Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis

Terminated
NCT04729517Phase 3

Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients

Completed
NCT01880840Phase 4

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

Completed
NCT00720382Phase 3

A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis

Completed
NCT00660829Phase 3

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed
NCT00660517Phase 3

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed
NCT01018862Phase 3

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

Completed
NCT00612118Phase 2

A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

Completed
NCT01368445Phase 3

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

Completed
NCT00712920Phase 3

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

Completed
NCT00979615Phase 4

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

Completed
NCT00845195Phase 4

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

Completed
NCT00720278Phase 3

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

Completed
NCT00824473Phase 3

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed
NCT00719862Phase 3

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Completed

All 16 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
16

External References

ChEMBL
CHEMBL1200809

Names & Codes

Research Codes

E-0659W-2979M